{
  "id": "albi_hcc",
  "title": "ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC)",
  "description": "Predicts survival in hepatocellular carcinoma patients based on serum albumin and bilirubin concentrations",
  "category": "hematology",
  "version": "2015",
  "parameters": [
    {
      "name": "albumin",
      "type": "float",
      "required": true,
      "description": "Serum albumin concentration",
      "validation": {
        "min": 1.0,
        "max": 6.0
      },
      "unit": "g/L"
    },
    {
      "name": "bilirubin",
      "type": "float",
      "required": true,
      "description": "Serum bilirubin concentration",
      "validation": {
        "min": 3.0,
        "max": 500.0
      },
      "unit": "μmol/L"
    }
  ],
  "result": {
    "name": "albi_score",
    "type": "float",
    "unit": "score",
    "description": "ALBI score with corresponding grade and median survival prediction"
  },
  "interpretation": {
    "ranges": [
      {
        "min": -10.0,
        "max": -2.6,
        "stage": "Grade 1",
        "description": "Best prognosis",
        "interpretation": "ALBI Grade 1 (score ≤-2.60). Median survival: 18.5 - 85.6 months. Best liver function and prognosis in HCC patients."
      },
      {
        "min": -2.6,
        "max": -1.39,
        "stage": "Grade 2",
        "description": "Intermediate prognosis",
        "interpretation": "ALBI Grade 2 (score >-2.60 to ≤-1.39). Median survival: 5.3 - 46.5 months. Intermediate liver function and prognosis in HCC patients."
      },
      {
        "min": -1.39,
        "max": 10.0,
        "stage": "Grade 3",
        "description": "Poorest prognosis",
        "interpretation": "ALBI Grade 3 (score >-1.39). Median survival: 2.3 - 15.5 months. Poorest liver function and prognosis in HCC patients."
      }
    ]
  },
  "references": [
    "Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-8. doi: 10.1200/JCO.2014.57.9151.",
    "Hiraoka A, Michitaka K, Kumada T, et al. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017;6(4):325-336. doi: 10.1159/000479984.",
    "Chen B, Lin S. Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine (Baltimore). 2017;96(24):e7142. doi: 10.1097/MD.0000000000007142."
  ],
  "formula": "ALBI = (log10 bilirubin × 0.66) + (albumin × -0.085), where bilirubin is in μmol/L and albumin in g/L",
  "notes": [
    "Alternative to Child-Pugh grade without subjective variables like ascites and encephalopathy",
    "Uses only objective laboratory measures of liver function",
    "Developed from international collaboration involving 1,313 Japanese HCC patients",
    "Validated across multiple geographical regions and clinical situations",
    "ALBI Grade 1: ≤-2.60, Grade 2: >-2.60 to ≤-1.39, Grade 3: >-1.39",
    "Survival depends on tumor stage, liver function, and performance status",
    "Applicable to HCC patients with or without underlying cirrhosis"
  ]
}